HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

External Evaluation For US FDA Food Safety ‘Structure, Function, Funding and Leadership’

Executive Summary

Members of Congress won’t find mention of criticism of FDA food safety oversight linked most recently to infant formula shortage in Commissioner Califf's announcement. He also didn’t refer to the formula shortage.

You may also be interested in...



Push For Separate US Food Agency Could Grow From Independent Panel’s ‘Urgent’ Call For Change

As latest evidence supporting their preference, lawmakers and other proponents of moving regulation of food manufacturing and marketing out of FDA and into a separate agency will reference report from panel appointed by Reagan-Udall Foundation at FDA Commissioner Robert Califf’s request.

‘Skinny’ US FDA User-Fee Reauthorization Would Omit Cosmetics, Supplement Regulation Reforms

Cosmetics and dietary supplement program reforms may have to wait if Republican Sen. Burr's stripped-down version of US FDA user-fee reauthorization package – which tracks with companion legislation already passed in the House – is the best Congress can do before the August recess.

House Appropriators Reject Docking FDA FY2023 Budget Until Formula Crisis Report Provided

First-term Iowa Republican Hinson had support from Democrat as well as other GOP members for withholding part of commissioner office’s FY2023 budget. Opposition from a self-acknowledged unlikely source, committee chair DeLauro, steered votes toward rejecting the proposal.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS152738

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel